Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 17/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639577 | 0.90 | CCR1 (0.69) | CCR1RAB9ACYP2C19KCNH2 | |
| SCHEMBL13184089 | 0.88 | CCR1 (0.61) | CCR1RAB9AALK | |
| SCHEMBL14724221 | 0.86 | CCR1 (0.62) | CCR1RAB9ACYP2C19KCNH2 | |
| SCHEMBL1911996 | 0.85 | KMT2A (0.56) | CCR1RAB9AALK | |
| SCHEMBL19002647 | 0.85 | ACHE (0.52) | CCR1RAB9AALK | |
| SCHEMBL22892278 | 0.85 | ADAMTS5 (0.53) | CCR1ALK | |
| SCHEMBL3631830 | 0.85 | CCR1 (0.60) | CCR1RAB9ACYP2C19KCNH2 | |
| SCHEMBL2876804 | 0.85 | CCR1 (0.60) | CCR1ALK | |
| SCHEMBL3063748 | 0.85 | CCR1 (0.63) | CCR1CYP2C19KCNH2 | |
| SCHEMBL13229291 | 0.84 | ALK (0.50) | CCR1RAB9AALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-1906965-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7777035-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885RAB9A 4494/4885CYP2C19 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.